Symphony Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Symphony Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-4,399	Closed	-$717K	–	284
2018 Q2	$717K	Sell	4,399 -95	-2%	-$14.7K	0.14%	136
2018 Q1	$732K	Sell	4,494 -322	-7%	-$52.6K	0.09%	194
2017 Q4	$722K	Sell	4,816 -73	-1%	-$10.8K	0.07%	217
2017 Q3	$743K	Sell	4,889 -36	-0.7%	-$5.42K	0.08%	216
2017 Q2	$634K	Sell	4,925 -239	-5%	-$28.8K	0.07%	240
2017 Q1	$565K	Sell	5,164 -1,112	-18%	-$97.9K	0.05%	265
2016 Q4	$463K	Sell	6,276 -217	-3%	-$17.7K	0.05%	294
2016 Q3	$566K	Sell	6,493 -6,295	-49%	-$595K	0.06%	251
2016 Q2	$1.1M	Sell	12,788 -5,773	-31%	-$499K	0.12%	172
2016 Q1	$1.48M	Buy	18,561 +10,475	+130%	+$947K	0.16%	146
2015 Q4	$1.02M	Sell	8,086 -279	-3%	-$33.7K	0.11%	191
2015 Q3	$871K	Sell	8,365 -209	-2%	-$26.9K	0.11%	209
2015 Q2	$1.06M	Sell	8,574 -1,122	-12%	-$141K	0.13%	173
2015 Q1	$1.14M	Buy	9,696 +855	+10%	+$102K	0.13%	164
2014 Q4	$1.05M	Sell	8,841 -3,813	-30%	-$429K	0.13%	164
2014 Q3	$1.42M	Buy	12,654 +3,194	+34%	+$304K	0.15%	138
2014 Q2	$895K	Sell	9,460 -464	-5%	-$32.5K	0.09%	236
2014 Q1	$702K	Buy	+9,924	New	+$786K	0.07%	252

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Symphony Asset Management's VRTX Position: Q3 2018 in Review

Symphony Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2018, closing a stake of 4,399 shares — an estimated $717K sold.

Symphony Asset Management first reported a position in VRTX in Q1 2014 and held it in 18 quarters. The position peaked at $1.48M in Q1 2016. 696 funds tracked by Wall St. Rank hold VRTX as of Q3 2018.

Symphony Asset Management reported no remaining Vertex Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Symphony Asset Management sold 4,399 Vertex Pharmaceuticals shares in Q3 2018, an estimated $717K.
Symphony Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2014 and held it in 18 quarters.
Symphony Asset Management's Vertex Pharmaceuticals position peaked at $1.48M in Q1 2016.
696 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2018.

Based on Symphony Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.